Which Is the Optimal Scan Time of 18F-DOPA PET/CT in Patients With Recurrent Medullary Thyroid Carcinoma?: Results From a Dynamic Acquisition Study.


Journal

Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109

Informations de publication

Date de publication:
Mar 2020
Historique:
pubmed: 25 1 2020
medline: 28 5 2020
entrez: 25 1 2020
Statut: ppublish

Résumé

The aim of this retrospective study was to determine, by dynamic acquisition, the optimal scan time of F-DOPA PET/CT in patients with recurrent medullary thyroid carcinoma (MTC). Twenty-one patients with suspected recurrent MTC underwent dynamic F-DOPA PET/CT (lasting 45 minutes) followed by whole-body scan. Three different time intervals of dynamic acquisition were evaluated: ultra-early phase (2-5 minutes), early phase (5-10 minutes), and late phase (40-45 minutes). The number and SUVmax of all detected lesions among the 3 dynamic acquisition phases were compared on qualitative and semiquantitative analyses. Time-activity curves, SUVmax washout rate between ultra-early or early phase and late phase, and signal-to-noise ratio (SNR) between lesion and background activity were also calculated. At dynamic acquisition, 15 of 21 patients were classified as PET-positive and 6 of 21 as PET-negative, with overall 21 detected lesions. Ultra-early and early imaging provided a better lesion visualization than late phase in more than 70% of cases, as also reflected by SNR (mean SNR reduction between 2 and 45 minutes, -45% ± 19%). Time-activity curves showed a rapid tracer accumulation in MTC lesions, with an average maximum uptake at 2 minutes after injection. Mean lesion SUVmax was 2-fold higher in ultra-early frames compared with last frames (mean washout rate, -44% ± 33%). Finally, compared with whole-body imaging in the same field of view, dynamic acquisition identified 1 additional positive patient and 3 additional lesions in 2 patients. Our study, showing a very fast F-DOPA uptake in MTC lesions, suggests the utility to obtain early PET/CT images, already at 2 to 5 minutes after tracer injection, when maximum lesion tracer uptake is reached.

Identifiants

pubmed: 31977485
doi: 10.1097/RLU.0000000000002925
pii: 00003072-202003000-00031
doi:

Substances chimiques

fluorodopa F 18 2C598205QX
Dihydroxyphenylalanine 63-84-3

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e134-e140

Références

Pacini F, Castagna MG, Cipri C, et al. Medullary thyroid carcinoma. Clin Oncol. 2010;22:475–485.
Kebebew E, Ituarte PH, Siperstein AE, et al. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88:1139–1148.
Pellegriti G, Leboulleux S, Baudin E, et al. Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. Br J Cancer. 2003;88:1537–1542.
Treglia G, Castaldi P, Villani MF, et al. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2012;39:569–580.
Beuthien-Baumann B, Strumpf A, Zessin J, et al. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2007;34:1604–1609.
Beheshti M, Pocher S, Vali R, et al. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur Radiol. 2009;19:1425–1434.
Kauhanen S, Schalin-Jäntti C, Seppänen M, et al. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer. J Nucl Med. 2011;52:1855–1863.
Koopmans KP, de Groot JWB, Plukker JTM, et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med. 2008;49:524–531.
Rasul S, Hartenbach S, Rebhan K, et al. [18F]DOPA PET/ceCT in diagnosis and staging of primary medullary thyroid carcinoma prior to surgery. Eur J Nucl Med Mol Imaging. 2018;45:2159–2169.
Romero-Lluch AR, Cuenca-Cuenca JI, Guerrero-Vázquez R, et al. Diagnostic utility of PET/CT with 18F-DOPA and 18F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff. Eur J Nucl Med Mol Imaging. 2017;44:2004–2013.
Verbeek HH, Plukker JT, Koopmans KP, et al. Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma. J Nucl Med. 2012;53:1863–1871.
Hoegerle S, Altehoefer C, Ghanem N, et al. 18F-DOPA positron emission tomography for tumor detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med. 2001;28:64–71.
Taïeb D, Timmers HJ, Hindié E, et al. EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2012;39:1977–1995.
Soussan M, Nataf V, Kerrou K, et al. Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer. Nucl Med Commun. 2012;33:775–779.
Treglia G, Stefanelli A, Castaldi P, et al. A standardized dual-phase 18F-DOPA PET/CT protocol in the detection of medullary thyroid cancer. Nucl Med Commun. 2013;34:185–186.
Archier A, Heimburger C, Guerin C, et al. (18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2016;43:1027–1033.
Golubić AT, Pasini Nemir E, Žuvić M, et al. The value of 18F-DOPA PET/CT in patients with medullary thyroid carcinoma and increased calcitonin values. Nucl Med Commun. 2017;38:636–641.
Hentschel M, Rottenburger C, Boedeker CC, et al. Is there an optimal scan time for 6-[F-18]fluoro-l-DOPA PET in pheochromocytomas and paragangliomas? Clin Nucl Med. 2012;37:e24–e29.
Imperiale A, Bahougne T, Goichot B, et al. Dynamic 18F-FDOPA PET findings after carbidopa premedication in 2 adult patients with insulinoma-related hyperinsulinemic hypoglycemia. Clin Nucl Med. 2015;40:682–684.
Koopmans KP, Neels ON, Kema IP, et al. Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results. Crit Rev Oncol Hematol. 2009;71:199–213.
Santhanam P, Taïeb D. Role of (18)F-FDOPA PET/CT imaging in endocrinology. Clin Endocrinol (Oxf). 2014;81:789–798.
Fiebrich HB, de Jong JR, Kema IP, et al. Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour. Eur J Nucl Med Mol Imaging. 2011;38:1854–1861.

Auteurs

Silvia Taralli (S)

From the UOC di Medicina Nucleare.

Margherita Lorusso (M)

From the UOC di Medicina Nucleare.

Valerio Lanni (V)

From the UOC di Medicina Nucleare.

Luca Indovina (L)

UOC di Fisica Sanitaria, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH